Fabrazyme (agalsidase beta) has been chosen to treat more than 5000 Fabry disease patients worldwide, regardless of disease severity, enzyme activity, or type of genetic variation.LEARN ABOUT HOW FABRAZYME CAN HELP
FABRAZYME IS THE ONLY ERT INDICATED FOR PATIENTS 2 YEARS OF AGE AND OLDER THAT HAS PROVEN LONG TERM EFFICACY AND SAFETY.
INDICATION AND USAGE
Fabrazyme is indicated for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease.
ERT=Enzyme replacement therapy